The case

The device was already approved in China. The application extended the approved anatomical scope to further structural regions of the same organ. The device itself did not change.

In its deficiency letter, NMPA asked for three things. Describe the diseases and surgical procedures at each new anatomical site. Cite the applicable clinical practice guidelines. Show that the approved indication is representative of the new ones.

Where the difficulty lies

The difficulty was not a lack of evidence. It was the structure of the argument. A common mistake is to list the diseases and procedures for each new site, attach references and stop there.

Reviewers need a complete chain of reasoning from validated data to the safety of the new indication. Every link in that chain must be stated, so the reviewer does not have to infer it.

A three-pillar framework

We studied the surgical techniques, the haemodynamic conditions and the mechanical performance of the device. We referred to national standards, international standards and expert consensus. On that basis we built three pillars.

1. Completeness. For each new site we mapped the main indications, standard procedures and device use scenarios to international guidelines and Chinese Medical Association recommendations. This established a clear clinical need at each site, and guideline support for the device category.
2. Representativeness (the core pillar). We identified the most mechanically demanding condition within the approved indication and set it as the performance ceiling. We then compared anatomical continuity, haemodynamic conditions and surgical technique. The comparison showed that the clinical data from the approved indication cover the full mechanical working range of every new site.
3. Scientific rigour. Engineering models gave a quantitative estimate of the load on the device at each site. We calculated safety factors against the material test data. Under the most conservative assumptions, the highest-stress scenario still had a safety factor several times above the threshold. All other sites fell within the performance envelope.

Result

The response was submitted and accepted by NMPA. The project confirmed that a “performance envelope plus substantial equivalence” argument works for this type of submission.

What carries over to other submissions

Data and references are necessary but not sufficient. The quality of a regulatory response depends on whether its logical structure is easy for the reviewer to follow. The main work is stating the implicit reasoning and integrating evidence from several disciplines into one framework.

The same reasoning applies beyond cardiovascular implants: the approved worst case covers the less demanding new sites. It is also useful for indication expansions of orthopaedic fixation devices, endovascular stents and other structural implants.